Literature DB >> 33002130

CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy.

Sarah Leong1, Sarah Inglott2, Foteini Papaleonidopoulou3, Karen Orfinada4, Philip Ancliff2, Jack Bartram2, Ben Carpenter1, Adele K Fielding1,3, Sara Ghorashian2, Victoria Grandage1, Rajeev Gupta1,3, Rachael Hough1, Asim Khwaja1,3, Vesna Pavasovic2, Anupama Rao2, Sujith Samarasinghe2, Ajay Vora2, Marc R Mansour1,3, David O'Connor2,3.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 33002130      PMCID： PMC7556151          DOI： 10.1182/bloodadvances.2020002502

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  24 in total

1.  Validation of cell-based fluorescence assays: practice guidelines from the International Council for Standardization of Haematology and International Clinical Cytometry Society.

Authors: 
Journal:  Cytometry B Clin Cytom       Date:  2013 Sep-Oct       Impact factor: 3.058

2.  Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia.

Authors:  Chezi Ganzel; Mira Kharit; Chen Duksin; Jacob M Rowe
Journal:  Haematologica       Date:  2018-06-28       Impact factor: 9.941

Review 3.  Cytokines and immunodeficiency diseases.

Authors:  W J Leonard
Journal:  Nat Rev Immunol       Date:  2001-12       Impact factor: 53.106

4.  Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies.

Authors:  Yi Tian Png; Natasha Vinanica; Takahiro Kamiya; Noriko Shimasaki; Elaine Coustan-Smith; Dario Campana
Journal:  Blood Adv       Date:  2017-11-21

5.  A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.

Authors:  Fengtao You; Yinyan Wang; Licui Jiang; Xuejun Zhu; Dan Chen; Lei Yuan; Gangli An; Huimin Meng; Lin Yang
Journal:  Am J Cancer Res       Date:  2019-01-01       Impact factor: 6.166

6.  T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).

Authors:  David I Marks; Elisabeth M Paietta; Anthony V Moorman; Susan M Richards; Georgina Buck; Gordon DeWald; Adolfo Ferrando; Adele K Fielding; Anthony H Goldstone; Rhett P Ketterling; Mark R Litzow; Selina M Luger; Andrew K McMillan; Marc R Mansour; Jacob M Rowe; Martin S Tallman; Hillard M Lazarus
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

7.  Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia.

Authors:  David O'Connor; Anthony V Moorman; Rachel Wade; Jeremy Hancock; Ronald M R Tan; Jack Bartram; John Moppett; Claire Schwab; Katharine Patrick; Christine J Harrison; Rachael Hough; Nick Goulden; Ajay Vora; Sujith Samarasinghe
Journal:  J Clin Oncol       Date:  2017-01-03       Impact factor: 44.544

8.  Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.

Authors:  Catriona Parker; Rachel Waters; Carly Leighton; Jeremy Hancock; Rosemary Sutton; Anthony V Moorman; Philip Ancliff; Mary Morgan; Ashish Masurekar; Nicholas Goulden; Nina Green; Tamas Révész; Philip Darbyshire; Sharon Love; Vaskar Saha
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

9.  Harnessing immunotherapy for pediatric T-cell malignancies.

Authors:  Caroline Diorio; David T Teachey
Journal:  Expert Rev Clin Immunol       Date:  2020-02-27       Impact factor: 5.124

10.  An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.

Authors:  Matthew L Cooper; Jaebok Choi; Karl Staser; Julie K Ritchey; Jessica M Devenport; Kayla Eckardt; Michael P Rettig; Bing Wang; Linda G Eissenberg; Armin Ghobadi; Leah N Gehrs; Julie L Prior; Samuel Achilefu; Christopher A Miller; Catrina C Fronick; Julie O'Neal; Feng Gao; David M Weinstock; Alejandro Gutierrez; Robert S Fulton; John F DiPersio
Journal:  Leukemia       Date:  2018-02-20       Impact factor: 11.528
View more
  3 in total

1.  A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells.

Authors:  Caterina Riillo; Daniele Caracciolo; Katia Grillone; Nicoletta Polerà; Franca Maria Tuccillo; Patrizia Bonelli; Giada Juli; Serena Ascrizzi; Francesca Scionti; Mariamena Arbitrio; Mariangela Lopreiato; Maria Anna Siciliano; Simona Sestito; Gabriella Talarico; Eulalia Galea; Maria Concetta Galati; Licia Pensabene; Giovanni Loprete; Marco Rossi; Andrea Ballerini; Massimo Gentile; Domenico Britti; Maria Teresa Di Martino; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Cancers (Basel)       Date:  2022-06-11       Impact factor: 6.575

2.  Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.

Authors:  Marco Cerrano; Massimiliano Bonifacio; Matteo Olivi; Antonio Curti; Michele Malagola; Michelina Dargenio; Anna Maria Scattolin; Cristina Papayannidis; Fabio Forghieri; Carmela Gurrieri; Ilaria Tanasi; Patrizia Zappasodi; Roberta La Starza; Nicola Stefano Fracchiolla; Patrizia Chiusolo; Luisa Giaccone; Maria Ilaria Del Principe; Fabio Giglio; Marzia Defina; Claudio Favre; Carmelo Rizzari; Barbara Castella; Giovanni Pizzolo; Felicetto Ferrara; Sabina Chiaretti; Robin Foà
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

3.  Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.

Authors:  Niklas Baumann; Christian Arndt; Judith Petersen; Marta Lustig; Thies Rösner; Katja Klausz; Christian Kellner; Miriam Bultmann; Lorenz Bastian; Fotini Vogiatzi; Jeanette H W Leusen; Renate Burger; Denis M Schewe; Matthias Peipp; Thomas Valerius
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.